BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Infection. 2017;45:131-138. [PMID: 28025726 DOI: 10.1007/s15010-016-0973-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Fiore V, Rastrelli E, Madeddu G, Ranieri R, De Vito A, Giuliani R, Di Mizio G, Bolcato M, De Matteis G, Ialungo AM, Dell'Isola S, Starnini G, Babudieri S. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects. BMC Infect Dis 2022;22:601. [PMID: 35799126 DOI: 10.1186/s12879-022-07565-2] [Reference Citation Analysis]
2 Supanan R, Han WM, Harnpariphan W, Ueaphongsukkit T, Ubolyam S, Sophonphan J, Tangkijvanich P, Thanprasertsuk S, Avihingsanon A; HIV-NAT HCV Study Team. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand. J Acquir Immune Defic Syndr 2021;88:465-9. [PMID: 34757974 DOI: 10.1097/QAI.0000000000002801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Fiore V, De Vito A, Pontali E, Lucania L, Madeddu G, Babudieri S. Chronic Viral Hepatitis in the Italian Prison Setting: Prevalence, Outcomes, Literature Needs and Perspectives. Healthcare (Basel) 2021;9:1186. [PMID: 34574960 DOI: 10.3390/healthcare9091186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, Bazazan A, Motamed-Gorji N, Sohrabpour A, Merat S, Poustchi H, Malekzadeh R. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy 2021;95:103269. [PMID: 33991887 DOI: 10.1016/j.drugpo.2021.103269] [Reference Citation Analysis]
5 Kondili LA, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Dig Liver Dis 2021:S1590-8658(21)00142-0. [PMID: 33926816 DOI: 10.1016/j.dld.2021.03.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Gaspar R, Liberal R, Tavares J, Morgado R, Macedo G. HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. World J Hepatol 2020; 12(12): 1314-1325 [PMID: 33442457 DOI: 10.4254/wjh.v12.i12.1314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hariri S, Sharafi H, Sheikh M, Merat S, Hashemi F, Azimian F, Tamadoni B, Ramazani R, Gouya MM, Abbasi B, Tashakorian M, Alasvand R, Alavian SM, Poustchi H, Malekzadeh R. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. Harm Reduct J 2020;17:80. [PMID: 33081794 DOI: 10.1186/s12954-020-00431-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One 2019;14:e0222196. [PMID: 31639131 DOI: 10.1371/journal.pone.0222196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kronfli N, Nitulescu R, Cox J, Moodie EE, Wong A, Cooper C, Gill J, Walmsley S, Martel-Laferrière V, Hull MW, Klein MB; Canadian Co-Infection Cohort Study. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. J Int AIDS Soc 2018;21:e25197. [PMID: 30460791 DOI: 10.1002/jia2.25197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
10 Mokkarala S, Johnson C, Sarkar S, Rudas RJ. Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population. J Correct Health Care 2019;25:134-42. [PMID: 30866706 DOI: 10.1177/1078345819832875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stöver H, Robaeys G, Lazarus JV. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J 2018;15:25. [PMID: 29751763 DOI: 10.1186/s12954-018-0230-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
12 Sharhani A, Mehrabi Y, Noroozi A, Nasirian M, Higgs P, Hajebi A, Hamzeh B, Khademi N, Noroozi M, Shakiba E, Etemad K. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.58739] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]